Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma

Area of Science:

• Oncology
• Hematology
• Cell Biology

Background:

• Circulating endothelial cells (CECs) are elevated in various solid cancers.
• CECs have not been systematically studied in osteosarcoma patients.

Purpose of the Study:

• To evaluate CEC and CEC progenitor cell (CEP) levels in patients with newly diagnosed high-grade osteosarcoma.
• To determine if CEC and CEP counts correlate with clinical features of osteosarcoma.

Main Methods:

• Prospective cohort study of 18 patients (12 months to 30 years) with newly diagnosed high-grade osteosarcoma.
• CEC and CEP quantification via flow cytometry using specific cell surface markers (CD146+, CD31+, CD45-, CD133+/-).
• Comparison of patient counts to seven age-matched healthy pediatric controls.

Main Results:

• No significant difference in CEC counts between osteosarcoma patients and healthy controls (P=0.12).
• No significant difference in CEP counts between osteosarcoma patients and healthy controls (P=0.69).
• CEC and CEP counts showed no correlation with metastatic status, tumor size, or chemotherapy response.

Conclusions:

• CEC and CEP levels are not elevated in osteosarcoma patients compared to controls.
• CECs and CEPs do not serve as reliable biomarkers for disease burden or treatment response in osteosarcoma.
• Novel biomarkers are required for effective management of osteosarcoma.